Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant factor VIIa - rEVO Biologics/LFB Biotechnologies

X
Drug Profile

Recombinant factor VIIa - rEVO Biologics/LFB Biotechnologies

Alternative Names: CEVENFACTA; COAGULATION FACTOR VIIA RECOMBINANT - rEVO Biologics/LFB; EPTACOG BETA ACTIVATED; LR 769; rhFVIIa; SEVENFACT; Sevenfact

Latest Information Update: 19 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GTC Biotherapeutics; LFB Biotechnologies
  • Developer HEMA Biologics; LFB Biotechnologies; rEVO Biologics
  • Class Blood coagulation factors; Coagulants; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A; Haemophilia B

Most Recent Events

  • 10 Dec 2022 Updated efficacy data from the phase III PERSEPT 1 trial in Haemophilia A and B presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 10 Dec 2022 Updated efficacy data from a phase III trial in Haemophilia A and B presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 25 Jul 2022 9363646: incorporated QC feedback
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top